Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein
/in Dendritic Cells, International Publications, Malignant MelanomaA phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
/in Dendritic Cells, International Publications, Multiple MyelomaImmunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Urothelial CarcinomaInfluence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells
/in Dendritic Cells, International Publications, Ovarian CancerAssociation of autologous AdHER2 dendritic cell vaccination with antitumor activity and number of circulating tumor cells.
/in Breast Cancer, Dendritic Cells, International PublicationsA phase III, double-blind, randomized clinical trial comparing S-1 in combination with DC vaccine loaded with WT1 peptides (TLP0-001) or placebo for the patients with advanced pancreatic cancer refractory to standard chemotherapy.
/in Dendritic Cells, International Publications, Pancreatic CancerImmunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International PublicationsProspect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International PublicationsImmunotherapeutic approaches for hepatocellular carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer